Today, we released new #clinical data for our lead allogeneic CAR-T program at #IMS24. These #data continue to validate the potential positive efficacy and safety of our platforms and technologies for the treatment of #myeloma. Read the press release: https://lnkd.in/e88MrKJN We will hold a #webcast conference call tomorrow, Saturday September 28 at 10am PT | 1pm ET to discuss the results. Details here: https://lnkd.in/euY5mmFc #CapacitytoCure #celltherapy International Myeloma Society
Poseida Therapeutics, Inc.
Biotechnology Research
San Diego, California 38,230 followers
The Capacity to Cure
About us
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com.
- Website
-
http://poseida.com/
External link for Poseida Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative Medicine, T-cells, Allogeneic, Oncology, Immuno-oncology, Immunology, Poseida, Cytotoxic T Lymphocytes, piggyBac®, piggyBac® DNA Modification System, Cas-CLOVER™, and TAL-CLOVER™
Locations
-
Primary
9390 Towne Centre Dr
200
San Diego, California 92121, US
Employees at Poseida Therapeutics, Inc.
Updates
-
We are proud to share 100% of our ITT population received treatment without need for bridging therapy or apheresis in our Phase 1b study of P-BCMA-ALLO1. More on this achievement and other clinical data now in Genetic Engineering & Biotechnology News: https://lnkd.in/dRrkAy4p #CapacitytoCure #celltherapy
-
We are thrilled to announce that Poseida has been recognized as one of Newsweek's Top 200 Most Loved Workplaces in the U.S.! A huge thank you to our incredible team for making this possible. Your hard work and support inspire us every day. Here’s to continuing our journey together. Details here: https://lnkd.in/dbkdE3rB #Top200 #CapacitytoCure #PoseidaProud Most Loved Workplaces®
-
Poseida Therapeutics, Inc. reposted this
Promising early results from Poseida Therapeutics, and good diversity in this phase 1 study, too.
Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
ajmc.com
-
#ICYMI: Hear more from Bhagirathbhai Dholaria, M.D., on our exciting #IMS24 clinical #data for P-BCMA-ALLO1 and how it could address significant unmet need in #myeloma. Full conference call webcast here: https://lnkd.in/e2WwceMK #CapacitytoCure #celltherapy
-
Poseida Therapeutics, Inc. reposted this
Patients show 91% response to allogeneic CAR-T therapy https://lnkd.in/e2YRdinH #Oncology #Haematology #Myeloma Poseida Therapeutics, Inc. Roche
-
Our CEO, Kristin Yarema, Ph.D., will be speaking at this year’s #FierceBiotechSummit on Sept. 30. Her panel will cover CAR-T drug development and #autoimmune upstarts. Details here: https://lnkd.in/gtM6CwrF #CapacitytoCure #celltherapy
-
Our Executive Chairman, Mark Gergen, shares why a bold vision and an agile team are necessary to push the boundaries of science and find new solutions for patients. Read more now: https://lnkd.in/ghUptpqd #biotech #leadership #innovation #strategy
Space, the final frontier . . .
Mark Gergen on LinkedIn
-
The FDA has just granted #RMAT designation for P-BCMA-ALLO1, our lead CAR-T program in development for relapsed/refractory multiple myeloma. This exciting milestone further validates Poseida’s differentiated approach. All details in our latest news: https://lnkd.in/gS_vVhQE #CapacitytoCure #celltherapy
-
September 15th marks 20 years of #lymphoma awareness efforts globally. We are proud to be working for a dedicated community seeking potential therapies with the #capacitytocure this life-threatening #cancer. #WLAD2024 #celltherapy #allogeneic